Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab

Rheumatology International

Volumn 32, Issue 3, 2012, Pages 795-798

  Yoo, Wan Hee ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Interstitial lung disease; Rituximab; Scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; DRUG DERIVATIVE; GLUCOCORTICOID; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE SCLERODERMA; DRUG RESISTANCE; DRUG TREATMENT FAILURE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG COMBINATION; DRUG SUBSTITUTION; FEMALE; MIDDLE AGED;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MYCOPHENOLIC ACID; SCLERODERMA, DIFFUSE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84863300540     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-009-1347-z     Document Type: Article

References (20)

1. Tashkin DP, ElashoV R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, RothWeld N, Metersky M, Scleroderma Lung Study Research Group (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655-2666
2. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary Wbrosis in scleroderma. Arthritis Rheum 54(12):3962-3970 (Pubitemid 44955900)
3. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP (2007) Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 27(4):357-361 (Pubitemid 46122279)
4. Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17(6):746-751 (Pubitemid 41546494)
5. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41(12):1123-1133 (Pubitemid 39346261)
6. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF (2006) B-lymphocyte depletion reduces skin Wbrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169(3):954-966 (Pubitemid 44411958)
7. Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, de Keyser F (2008) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis (epub ahead of print)
8. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60(2):578-583
9. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 47(4):552-553
10. Steen V (2004) Changes in causes of death in SSc over the past 30 years. Arthritis Rheum 50(S9)(Abstract 1052):S422
11. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr (1985) Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 28(7):759-767 (Pubitemid 15027329)
12. Maas D, Schramm A, Jackle B, Raif W, Schubothe H (1979) Progressive systemic sclerosis-long-term treatment with azathioprin (author's transl). Immun Infekt 7(5):165-169 (Pubitemid 10175217)
13. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE (2006) Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology (Oxford) 45(12):1572 (Pubitemid 44817068)
14. Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50(6):1918-1927 (Pubitemid 38725103)
15. WhitWeld ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-speciWc gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100(21):12319-12324 (Pubitemid 37271558)
16. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56(9):3167-3168 (Pubitemid 47502765)
17. Hasegawa M, Fujimoto M, Takehara K, Sato S (2005) Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue Wbrosis. J Dermatol Sci 39(1):1-7 (Pubitemid 40835827)
18. Bosello S, De Santis M, Lama G (2007) Clinical improvement in systemic slerosis patients treated with anti-CD20. Arthritis Rheum Sup 56:S494
19. Lombardi S, Quartuccio L, Franzolini N (2008) Rituximab for the long term treatment of severe cutaneous involvement in systemic sclerosis. Arthritis Rheum Sup 58:S822-S823
20. Adams AB, Barillas-Arias L, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA (2006) Cyclophosphamide and rituximab combination therapy for the treatment of juvenile onset scleroderma: 6 Patient Case Series. In: Proceedings of ACR/ ARHP annual scientific meeting 2006, Washington, DC, USA, pp 10-15